Trial tests alpelisib for MCAP with PIK3CA mutations
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This Phase 2 study tests alpelisib in children and adults with MCAP, a condition caused by a specific PIK3CA gene mutation. The goal is to see if the treatment is effective and safe, while carefully monitoring blood sugar and organ function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 2 to 40 when you sign consent (and assent if applicable).
- Have a confirmed MCAP diagnosis with a developmental learning/ability challenge.
- Have test-confirmed PIK3CA gene mutation in tumor/affected-tissue or body DNA using a local lab DNA test.
- Have blood and organ lab results that meet safety thresholds (blood counts, kidney, liver, electrolytes, and clotting).
- Be able to take the study medicine by mouth (tablets or suitable liquid form).
- If you can become pregnant (or have partners who can): agree to pregnancy prevention rules during the study and for 1 week after stopping.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, RLY-2608, that targets the specific genetic change (PIK3CA mutation) causing overgrowth conditions. It aims to see if the drug can slow or stop the growth of affected tissues.
This Phase 2 trial studies whether a targeted medicine that blocks MEK can work better than chemotherapy for certain slow-growing brain tumors in children. You may qualify if your tumor has specific genetic features and has not already been treated with non-surgery therapies.
This trial tests alpelisib (a targeted medicine) for people who have lymphatic malformations (LyM) that cause symptoms and have a PIK3CA mutation. It may help shrink or control these lesions when other procedures are delayed until after the first 24 weeks.
This trial tests a drug called alpelisib for children and adults with a rare overgrowth condition called PROS that is caused by a PIK3CA gene change. It aims to see if the drug can safely shrink overgrowth and improve symptoms.
This trial tests two targeted medicines for people with certain types of vascular malformations (abnormal blood vessels). If you have a slow-flow malformation, you may receive alpelisib; if you have a fast-flow malformation, you may receive mirdametinib. Genetic testing is needed to see if your malformation has a specific change that these drugs target.
This Phase 1 trial studies whether combining two targeted medicines—alpelisib and trametinib—can shrink or slow progressive meningiomas that have already been treated with standard surgery and radiation. If you qualify, you may help test a new treatment approach for tumors that keep growing.
Hear when a new Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.